Jordyn Fantuzzi

The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY)’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday.  The stock, which rallied ahead of the news, subsequently plunged as investors walked with profits — but...